Printer Friendly

BIOGEN ANNOUNCES PLANS TO EXPAND ON CAMBRIDGE SITE

 CAMBRIDGE, Mass., June 18 /PRNewswire/ -- Biogen, Inc. (NASDAQ: BGEN) today announced that it intends to build a major new facility in Cambridge, Mass.
 "Biogen will need significant additional laboratory and office space to sustain our current rate of growth, particularly as our flagship products enter the final phases of clinical testing and new research projects come into the pipeline," said Jim Vincent, Biogen's chairman. "After review of a number of potential sites both in Massachusetts and other states, we feel that remaining in Cambridge is our most attractive option at this time. We look forward to remaining a part of the Kendall Square biotech community."
 The first phase of the proposed expansion will be construction of a building of approximately 130,000 square feet, designed to house research laboratories and offices. Biogen has options to expand significantly on the site, which abuts its main laboratory building. Biogen currently occupies laboratory, production and office space in five buildings in Cambridge.
 Construction is scheduled to begin late this fall, with completion anticipated in 1995. The land is currently owned by the Cambridge Redevelopment Authority. Prior to the initiation of construction, the Cambridge City Council will have to review and approve a number of zoning, permitp)wg, an 4l


PRNEWSWIRE

PRNEWSWIRE

x issues.
 Biogen, Inc., headquartered in Cambridge, Mass, is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS and other cancers and viruses.
 -0- 6/18/93
 /CONTACT: Kathryn R. Bloom, director of communications for Biogen, Inc., 617-252-9851 (media); Amy S. Hedison, director, investor relations for Biogen, Inc., 617-252-9873 (investment community)/
 (BGEN)


CO: Biogen, Inc. ST: Massachusetts IN: MTC SU: RLE

CM -- NE004 -- 3453 06/18/93 09:19 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 18, 1993
Words:327
Previous Article:HEALTH RISK MANAGEMENT, INC. ANNOUNCES MANAGEMENT CHANGES AND MARKET-DRIVEN ORGANIZATIONAL STRUCTURE
Next Article:GTSI OFFERS ENERGY STAR-COMPLIANT PRODUCTS
Topics:


Related Articles
BIOGEN APPOINTS LAWRENCE S. DANIELS VICE PRESIDENT-MARKETING AND BUSINESS DEVELOPMENT
BIOGEN REPORTS SECOND QUARTER 1993 EARNINGS OF $5.6 MILLION VS. $0.7 MILLION IN SECOND QUARTER 1992
BIOGEN ANNOUNCES MANAGEMENT REALIGNMENT AS NEXT STEP IN TRANSITION FROM R&D ORGANIZATION TO OPERATING COMPANY
BIOGEN BREAKS GROUND FOR NEW RESEARCH CENTER IN CAMBRIDGE
BIOGEN ANNOUNCES THAT U.K. HIGH COURT UPHOLDS ITS PATENT ON HEPATITIS B ANTIGENS
BIOGEN REPORTS FIRST QUARTER EARNINGS OF $0.31 PER SHARE
Biogen Appoints Mona Haynes As Director Of Marketing
Biogen Dedicates New $60 Million Facility In Research Triangle Park, North Carolina
Biogen Announces That Board Of Directors Authorizes Repurchase Of Up To 2,500,000 Shares Of Common Stock
Biogen concludes its participation in LFA-1 antagonist drug development program.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters